GlassScriptPhysician profile
David A Wiles
NPI 1912459249
$7,599.41
in general payments reported to CMS, 2019-2025
23 companies · $1,953 in 2025
The $1,953 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,559 · 2022: $798 · 2023: $1,605 · 2024: $1,685 · 2025: $1,953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,243.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,440.22 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Eterna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,132.50 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $465.65 | 2021-2025 | Lifevest |
| Scpharmaceuticals INC. | $452.24 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $442.49 | 2021-2025 | |
| Pfizer INC. | $397.63 | 2021-2025 | |
| Abiomed | $379.84 | 2022-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $374.90 | 2021-2025 | Farxiga, Wainua |
| Actelion Pharmaceuticals US, INC. | $321.87 | 2021-2025 | Opsumit, Uptravi |
| Cvrx, INC. | $307.21 | 2023-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $174.87 | 2022-2024 | Verquvo, Winrevair, Keytruda |
| Lexicon Pharmaceuticals, INC. | $144.13 | 2023 | Inpefa |
| Impulse Dynamics (USA) INC. | $134.81 | 2024 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $82.45 | 2024-2025 | Eliquis, Camzyos |
| Kestra Medical Technology Services, INC. | $67.51 | 2024 | Assure Wcd |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $57.90 | 2023 | Resonate El Icd Vr |
| Lemaitre Vascular, INC. | $54.30 | 2025 | Artegraft Vascular Graft |
| Edwards Lifesciences Corporation | $53.55 | 2021-2024 | Sapien 3 Ultra Resilia |
| Daiichi Sankyo INC. | $28.03 | 2023 | Injectafer |
| Akcea Therapeutics, INC. | $24.32 | 2021 | |
| Shockwave Medical, INC | $23.54 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $21.85 | 2024 | Micra |
| Bayer Healthcare Pharmaceuticals INC. | $17.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wiles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.